Oct 18 (Reuters) – NuCana PLC: * NUCANA PRESENTS ENCOURAGING DATA ON NUC-7738 IN COMBINATION WITH PD-1 INHIBITORS USING PRIMARY PATIENT-DERIVED ORGANOIDS AND AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTES AT THE ESMO CONGRESS 2025 * NUCANA PLC – REGULATORS APPROVE STUDY EXPANSION FOR 28 MORE PATIENTS * NUCANA PLC – DATA TO DATE FROM NUTIDE:701 SHOWS FAVORABLE SAFETY AND TUMOR REDUCTION Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The post BRIEF-Nucana Says Data From Nutide:701 Shows Favorable Safety And Tumor Reduction appeared first on The Sunday Guardian.

See Full Page